When: FY27 Q1 earnings confirmation of forward EPS trajectory

Then: Re-engage trimmed position

SELL

• Trailing P/E of 24.47 versus forward P/E of 14.23 implies approximately 72% earnings growth required ($3.73 to $6.41 EPS)
• 50 SMA at 83.02 is below 200 SMA at 88.56, representing a bearish structural configuration
• RSI at 71.12 with price at the upper Bollinger Band indicates overbought conditions in a 2.5-month old trend
• Price has rallied 25% in ten weeks from a capitulation low and reclaimed the 200 SMA only 4 trading days ago
• Goodwill of $42.6 billion represents 46% of total assets with net margin of 13.2%
• Upside to 52-week high/102.48 is approximately 12-13% versus downside of 9% to 50 SMA and 19% to May low of 73.73
• Sentiment data is thin: only 7 news headlines, StockTwits unavailable, Reddit returned zero posts across wallstreetbets, stocks, and investing
• Structural risks include China VBP pricing pressure, intensifying diabetes competition from Dexcom, Abbott, and Tandem, and senior R&D executive departure
• Trim 30-50% on move toward 92-93, stop at 88.56, re-entry near 88-89

→ vs aggressive: Earnings math framing: the 72% gap is not a moving goalpost but a fixed market-implied requirement that one quarter of 17.8% growth cannot satisfy

→ vs aggressive: Structural re-rating claim: two quarters of revenue acceleration after a drawdown does not confirm regime change; 50 SMA below 200 SMA remains bearish

→ vs aggressive: RSI dismissal is alarming: RSI has never been this elevated in this recovery sequence, which is only 2.5 months old

→ vs aggressive: Sentiment being 'overwhelmingly constructive' is statistically thin—only 7 news sources drove the read with zero retail validation data

→ vs aggressive: Asymmetric upside claim is mathematically wrong: upside is 12-13% while downside is 9-19%

→ vs neutral: Hedging or silence is itself a position that exposes the firm to full downside while taking only partial upside

BUY (trim 30% at $92-$93, hold 70% with hedges)

• Q1 FY27 revenue of $9.81 billion and gross margin of 65.3% support a structural improvement thesis warranting more than 30% trim
• Hard stop at $88.56 (200 SMA) is too tight; ATR of $2.12 suggests a trailing stop of 2x ATR or closing stop below 10 EMA at $88.88 is more appropriate
• Re-entry should be tiered: 25% on pullback to 10 EMA at $88.88, 25% on pullback to 200 SMA at $88.56, 25% on confirmed bounce with momentum divergence
• Options hedge (put spread or collar) on remaining 70% position recommended given elevated RSI at 71 and unconfirmed moving average structure
• 3-4 month time stop required: if MDT fails to exceed November 2024 peak of $102.48, thesis is not materializing and full reassessment warranted
• Conservative analyst's asymmetry framing is incomplete without probability weights; 12-13% upside may be more likely than 19% downside if macro backdrop remains supportive
• A stable/no-cut macro regime is actively supportive for defensive growth names like MDT with yield above 3%, not merely neutral

→ vs aggressive: The 72% earnings growth embedded in forward P/E is what the market is pricing, not a bear case—ignoring valuation during a momentum phase risks paying any price; momentum phases end

→ vs aggressive: Golden cross argument doesn't define what to do in the 30% of cases that retest; many retrace to breakout level, 200 SMA, then prior low in lower highs sequence

→ vs aggressive: RSI at 71 in early regime change (50 SMA still below 200 SMA, stock just reclaimed 200 SMA 4 days ago) is precisely when pullback probability is highest—not bearish bias but how trend establishment works

→ vs aggressive: Calling 7 headlines 'overwhelmingly constructive' overstates confidence when the sentiment report itself notes low confidence due to 2 of 3 sources failing

→ vs conservative: Asymmetry framing ignores probability weights; the conservative analyst presents magnitudes without probability distribution, making the setup appear more bearish than warranted

→ vs conservative: Stable macro is optimal regime for defensive growth names like MDT, not merely neutral—dismissing it as 'no tailwind' understates the actual support

→ vs conservative: Presenting the trader's plan as the 'only rational way' is itself a form of confirmation bias; other defensible approaches include full hold with tighter trailing stop, partial trim with options hedge, or full hold accepting volatility

→ vs conservative: Technical warnings (unconfirmed MA stack, stretched RSI) warrant position sizing and caution, not exit at upper Bollinger Band for a stock with record revenue, expanding margins, and clear catalyst pipeline